Investigation of interindividual factors in nivolumab pharmacokinetics and adverse events in Japanese patients with non-small-cell lung cancer and renal cell cancer

Investigation of interindividual factors in nivolumab pharmacokinetics and adverse events in Japanese patients with non-small-cell lung cancer and renal cell cancer - Investigation of interindividual factors in nivolumab pharmacokinetics and adverse events in Japanese patients with non-small-cell lung cancer and renal cell cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041082

Enrollment

100

Registered

2020-07-13

Start date

2018-01-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small-cell lung cancer, renal cell cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients treated with intravenous nivolumab for non-small-cell lung cancer or renal cell cancer 2. Patients receiving written informed consent

Exclusion criteria

Exclusion criteria: Patients who are judged by physicians as inappropriate for study enrollment

Design outcomes

Primary

Measure	Time frame
Serum nivolumab concentration just before dosing at 7th administration or later	—

Countries

Japan

Contacts

Public ContactTakafumi Naito

Hamamatsu University School of Medicine Department of Hospital pharmacy

pharmacyham-adm@umin.ac.jp053-435-2763

Outcome results